Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Bangkok Genomics Innovation PCL EV-to-EBIT?
Bangkok Genomics Innovation PCLBKK:BKGI 46 EV-to-EBIT is 11.56 as of Sep. 15, 2026, which is 29% below its 10-year median of 16.37. GuruFocus rates BKK:BKGI with a GF Score™ of 46/100. The stock has 11 warning signs investors should review. Among 109 Medical Diagnostics & Research companies, Bangkok Genomics Innovation PCL ranks better than 75.23% on this metric.
The historical rank and industry rank for Bangkok Genomics Innovation PCL's EV-to-EBIT or its related term are showing as below:
BKK:BKGI'
s EV-to-EBIT Range Over the Past 10 Years
Min: 6.37 Med: 16.37 Max: 93.13
Current: 11.56
During the past 7 years, the highest EV-to-EBIT of Bangkok Genomics Innovation PCL was 93.13. The lowest was 6.37. And the median was 16.37.
BKK:BKGI's EV-to-EBIT is ranked better than 75.23% of 109
companies
in the Medical Diagnostics & Research industry
Industry Median: 24.71
vs BKK:BKGI: 11.56
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Bangkok Genomics Innovation PCL's Enterprise Value for the quarter that ended in Jun. 2026 was ฿1,013.8 Mil.
Bangkok Genomics Innovation PCL's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿105.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bangkok Genomics Innovation PCL EV-to-EBIT Related Terms
Bangkok Genomics Innovation PCL EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Bangkok Genomics Innovation PCL's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bangkok Genomics Innovation PCL EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Bangkok Genomics Innovation PCL's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Bangkok Genomics Innovation PCL's EV-to-EBIT falls into.
Bangkok Genomics Innovation PCL's current Enterprise Value is ฿1,217.8 Mil.
Bangkok Genomics Innovation PCL's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿105.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bangkok Genomics Innovation PCL (BKK:BKGI) has a EV-to-EBIT of 11.56 as of Sep. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bangkok Genomics Innovation PCL and its competitors. This is 29% below median its historical median of 16.37. Over the past decade, Bangkok Genomics Innovation PCL's EV-to-EBIT has ranged from 6.37 to 93.13. According to the industry distribution chart, Bangkok Genomics Innovation PCL ranks #27 out of 109 companies in the Medical Diagnostics & Research industry, placing it in the top 24.8%.
Is Bangkok Genomics Innovation PCL's EV-to-EBIT too high?
Bangkok Genomics Innovation PCL's current EV-to-EBIT of 11.56 is 29% below median its 10-year median of 16.37. Over the past 10 years, this metric has ranged from a low of 6.37 to a high of 93.13. The Medical Diagnostics & Research industry median EV-to-EBIT is 24.71. Bangkok Genomics Innovation PCL's value of 11.56 is 53.2% below this industry median. Based on the distribution chart, Bangkok Genomics Innovation PCL ranks #27 out of 109 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Bangkok Genomics Innovation PCL has a GF Score™ of 46/100, reflecting its overall financial health beyond just this single metric.
How does Bangkok Genomics Innovation PCL's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Bangkok Genomics Innovation PCL ranks #27 out of 109 companies for EV-to-EBIT. This places Bangkok Genomics Innovation PCL in the top 25% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 24.71. Bangkok Genomics Innovation PCL's value of 11.56 is 53.2% below this benchmark. Historically, Bangkok Genomics Innovation PCL's own EV-to-EBIT has ranged from 6.37 to 93.13 over the past decade. While the company's 10-year median is 16.37 vs. the industry median of 24.71, Bangkok Genomics Innovation PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 24.71, based on 109 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bangkok Genomics Innovation PCL's current EV-to-EBIT of 11.56 is 53.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Bangkok Genomics Innovation PCL and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 24.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bangkok Genomics Innovation PCL's current EV-to-EBIT is 11.56, which is 29% below median its own 10-year median of 16.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Genomics Innovation PCL stock overvalued right now?
Bangkok Genomics Innovation PCL (BKK:BKGI) has a current EV-to-EBIT of 11.56. The current EV-to-EBIT is 11.56, which is 29% below median its 10-year median of 16.37 and 53.2% below the Medical Diagnostics & Research industry median of 24.71. Bangkok Genomics Innovation PCL's overall GF Score™ is 46/100 with 11 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Bangkok Genomics Innovation PCL (BKK:BKGI), the current EV-to-EBIT is 11.56 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bangkok Genomics Innovation PCL operate a laboratory and provide medical analysis services. Its services includes Screening for genetic abnormalities in reproductive health (Reproductive Health Testing Services),Infectious Disease Analysis Product Group (Infectious - Related Testing Services), Other screening product groups (Other Testing Services), providing technology services (Tech Solution Services), and Sales of other medical products Related (Medical - Related Products). Its segments include Sale of laboratory reagents and related products; Testing and analysis services, which derives maximum revenue; and Sale and advanced therapy medicinal product.
46GF Score
Get the complete analysis for BKK:BKGI
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:BKGI has been successfully added to your 
